You are herePharma News

Pharma News

US FDA Approves Neupogen as First Drug To Treat Sickness Due to Radiation Exposure

US Food and Drug Administration (FDA) has approved  Neupogen, a drug originally used to treat side effects of chemotherapy,is the first ever approved for the treatment of acute radiation injury and the approval came as a result of research performed by the University of Maryland School of Medicine (UM SOM) scientists.

Janssen's Imbruvica get EMA recommendation to treat Waldenstrom’s macroglobulinaemia

The European Medicines Agency (EMA) has recommended extending the use of Imbruvica (ibrutinib) for treatment of patients with Waldenstrom’s macroglobulinaemia. The medicine is indicated for adults who have received at least one prior therapy or as a first line treatment for patients unsuitable for chemo-immunotherapy.

Aura Biosciences receives US FDA orphan drug designation for novel treatment of uveal melanoma

The US Food and Drug Administration (FDA) granted Orphan Drug Designation to Aura Biosciences' drug AU-011 for the treatment of uveal melanoma. The FDA’s Orphan Drug Designation programme provides orphan status to drugs and biologics, which demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions in the US.

Apollo White Dental launches 'HOLI-DENT' scheme to involve travellers for dental treatment in India

Apollo White Dental launched 'HOLI-DENT' scheme to involve travellers who want dental treatment in India.

Global Action Plan on Anti-Microbial Resistance adopted by India

The Minister of Health & Family Welfare Shri Jagat Prakash Nadda successfully steered the proceedings of the 68th Session of the World Health Assembly in his capacity as its President. It was after a gap of 19 years that India assumed the Presidency of the World Health Assembly, the highest decision making body of the World Health Organisation. The 68th WHA took place in Geneva from 18-26 May 2015.

VTU Technology & Biomay entered into agreement for production of recombinant allergen

VTU Technology and Biomay, based in Vienna, the two leading Austrian biotechnology companies, entered into a licensing agreement for the production of recombinant allergens. VTU Technology, currently offering a very broad and versatile technology platform available for Pichia pastoris protein production. VTU Technology´s Pichia platform - standing out due to its diversity of expression tools and ingenious expression strategies - enables the production of high-performance expression strains, high-quality proteins and economically, viable protein production processes.

Mabspace Biosciences signed a collaborative contract of a novel therapeutic antibody with genor biopharma

MabSpace Biosciences Co., Ltd, a biotechnology company focused on the discovery and early development of antibody based therapeutics,  has signed a collaborative contract of a novel therapeutic antibody with Genor Biopharma Co. Ltd (GenorBio), the mAb division of Walvax Group, one of the leading therapeutic antibody development companies in China.

Researchers found Ebola Virus's Achilles' Heel

An international team including scientists from Albert Einstein College of Medicine of Yeshiva University and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has identified the molecular “lock” that the deadly Ebola virus must pick to gain entry to cells. The findings, made in mice, suggest that drugs blocking entry to this lock could protect against Ebola infection.

Artificial muscles developed from onion cells

The humble onion is proving its strength outside the culinary world, enabling scientists to develop artificial muscles by using gold-plated cells of the vegetable. Unlike previous artificial muscles, this one, created by a group of researchers from National Taiwan University, can either expand or contract to bend in different directions depending on the driving voltage applied.

Glenmark Pharma gets tentative ANDA approval from US FDA for rufinamide tablets USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received US FDA tentative ANDA approval for its rufinamide tablets USP, 200 mg and 400 mg.